Opioid Induced Constipation Treatment Market Size Share Trends Forecast 2026

Opioid Induced Constipation Treatment Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
 
SEATTLE - Oct. 12, 2020 - PRLog -- Opioid Induced Constipation Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Opioids are medications that work on opioid receptors in order to generate morphine-like effects. These are mainly used therapeutically to relieve pain and are often abused by individuals addicted to them.

According to a report by National Center for Biotechnology Information, chronic pain is a persistent pain that lingers for 3 months or more. The occurrence of chronic pain in the population is 10–15%. In individuals with chronic non-cancer pain, the commonness of opioid induced constipation varies from 41% to 81%.

Rising number of patients using illegal medicines and deferred use of opioids in the therapy of chronic pain are some of the key factors driving growth of the opioid induced constipation (OIC) treatment market. Moreover, it has been observed that the untapped market for advantageous, successful and safe therapeutic solutions in OIC drug is extensive and developing at a fast pace, especially in developed regions.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/opioid-induced-constipation-treatment-market-202

Prevalence of opioid induced constipation is rising considerably. According to the American Academy of Pain Medicine (AAPM), around 100 million patients in the U.S. suffered from opioid induced constipation in 2013. Furthermore, AAPM also estimated that the number of occurrences would rise, owing to the increase in the number of individuals taking opioid drugs.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/202

Some of the major companies operating in the opioid induced constipation treatment market in the current scenario are Daewoong Co. Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Cosmo Pharmaceuticals, AstraZeneca plc, Abbott Laboratories, Valeant Pharmaceuticals, C.B. Fleet Company, Inc., and Bayer AG.

Key Developments

Key players in the market are focused on various business strategies such as gaining product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in December 2018, Shionogi BV, the European subsidiary of Shionogi & Co., Ltd, received approval for Symproic (naldemedine) from European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP). Symproic is indicated for the treatment of opioid-induced constipation in adults.

Major companies in the market are focused on various growth strategies such as merger and acquisition, in order gain competitive edge in the market.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/202

Contact
Mr. Shah
sales@coherentmarketinsights.com
+1-206-701-6702
End
Email:***@coherentmarketinsights.com
Posted By:***@coherentmarketinsights.com Email Verified
Tags:Healthcare
Industry:Health
Location:Seattle - Washington - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Coherent Market Insights News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share